Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Anticancer Res. 2019 Nov;39(11):6193-6196. doi: 10.21873/anticanres.13827.
BACKGROUND/AIM: Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival.
Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis.
The median CA19-9 did not decrease in the cohort after IRE treatment (282 U/ml before versus 315 U/ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01).
IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.
背景/目的：糖类抗原 19-9（CA19-9）是胰腺癌的肿瘤标志物。不可逆电穿孔（IRE）是一种治疗胰腺癌的实验方法。本研究旨在评估经皮 IRE 是否降低胰腺癌患者的 CA19-9 水平，以及这是否与改善总体生存率相关。
71 例局部晚期胰腺癌或切除后局部复发的患者接受了治疗。排除了缺乏数据、转移性疾病和 IRE 前 CA19-9 正常的患者。这使得 35 例病例可供分析。
IRE 治疗后队列的中位 CA19-9 没有降低（IRE 治疗前为 282 U/ml，IRE 治疗后为 315 U/ml；p=0.80）。CA19-9 最佳反应组的 25%患者的总体生存率优于最差反应组的 25%患者（平均分别为 13.1 个月和 8.1 个月；p=0.01）。
IRE 并未降低胰腺癌患者的 CA19-9 水平。然而，CA19-9 的反应与生存率的提高相关。
